Continued strong Cresemba® (isavuconazole) sales trigger second sales milestone this year from Pfizer to Basilea of USD 7 million

    NEXT STORY
    Half-year report
    PREV STORY
    ASLAN Pharmaceuticals Announces Closing of US$15 Million Public Offering of American Depositary Shares, Including Full Exercise of Underwriter’s Option to Purchase Additional ADSs
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Clearside Biomedical Announces Positive Topline Results from Phase 2 Clinical Trial of CLS-TA Used with Eylea in Patients with Diabetic Macular Edema

    Primary and Secondary Endpoints Met in 6-month TrialPatients Treated with CLS-TA Achieved Comparable Vision ...

    author_avatar
    NASDAQ Market News

    Merus Announces Ono Pharmaceuticals Exercise of its Option for New Research and License Agreement to Generate Bispecific Antibody Targeting Autoimmune Diseases

    UTRECHT, The Netherlands, March 14, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology ...

    author_avatar
    NASDAQ Market News

    Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial

    author_avatar
    NASDAQ Market News